DK0710657T3 - Adhæsionsreceptor-antagonister - Google Patents
Adhæsionsreceptor-antagonisterInfo
- Publication number
- DK0710657T3 DK0710657T3 DK95116483T DK95116483T DK0710657T3 DK 0710657 T3 DK0710657 T3 DK 0710657T3 DK 95116483 T DK95116483 T DK 95116483T DK 95116483 T DK95116483 T DK 95116483T DK 0710657 T3 DK0710657 T3 DK 0710657T3
- Authority
- DK
- Denmark
- Prior art keywords
- receptor antagonists
- adhesion receptor
- opt
- formula
- so2ar
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/18—Oxygen atoms
- C07D263/20—Oxygen atoms attached in position 2
- C07D263/24—Oxygen atoms attached in position 2 with hydrocarbon radicals, substituted by oxygen atoms, attached to other ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE4439110 | 1994-11-02 | ||
DE19509093A DE19509093A1 (de) | 1994-11-02 | 1995-03-16 | Adhäsionsrezeptor-Antagonisten |
Publications (1)
Publication Number | Publication Date |
---|---|
DK0710657T3 true DK0710657T3 (da) | 1999-05-25 |
Family
ID=25941621
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK95116483T DK0710657T3 (da) | 1994-11-02 | 1995-10-19 | Adhæsionsreceptor-antagonister |
Country Status (19)
Country | Link |
---|---|
US (2) | US6602876B1 (da) |
EP (1) | EP0710657B1 (da) |
JP (1) | JP3810837B2 (da) |
CN (1) | CN1067384C (da) |
AT (1) | ATE170179T1 (da) |
AU (1) | AU698987B2 (da) |
BR (1) | BR9505039A (da) |
CA (1) | CA2161857C (da) |
CZ (1) | CZ290658B6 (da) |
DK (1) | DK0710657T3 (da) |
ES (1) | ES2123889T3 (da) |
FI (1) | FI955223A (da) |
HU (1) | HU217437B (da) |
MX (1) | MX9504630A (da) |
NO (1) | NO305246B1 (da) |
PL (1) | PL182291B1 (da) |
RU (1) | RU2165928C2 (da) |
SK (1) | SK282123B6 (da) |
TR (1) | TR199501359A2 (da) |
Families Citing this family (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0710657B1 (de) * | 1994-11-02 | 1998-08-26 | MERCK PATENT GmbH | Adhäsionsrezeptor-Antagonisten |
DE19516483A1 (de) * | 1995-05-05 | 1996-11-07 | Merck Patent Gmbh | Adhäsionsrezeptor-Antagonisten |
US7053041B1 (en) * | 1996-05-31 | 2006-05-30 | The Scripps Research Institute | Methods and compositions useful for inhibition of αvβ5mediated angiogenesis |
WO1997029701A1 (en) | 1996-02-15 | 1997-08-21 | Biosense Inc. | Catheter based surgery |
US6443974B1 (en) | 1996-07-28 | 2002-09-03 | Biosense, Inc. | Electromagnetic cardiac biostimulation |
US5900414A (en) * | 1996-08-29 | 1999-05-04 | Merck & Co., Inc. | Methods for administering integrin receptor antagonists |
EP0917878A4 (en) * | 1997-02-26 | 2004-05-19 | Toray Industries | REMEDIES FOR HEPATITIS |
DE19755268A1 (de) * | 1997-12-12 | 1999-06-17 | Merck Patent Gmbh | Benzamidinderivate |
US6197794B1 (en) | 1998-01-08 | 2001-03-06 | Celltech Therapeutics Limited | Phenylalanine derivatives |
US6329372B1 (en) | 1998-01-27 | 2001-12-11 | Celltech Therapeutics Limited | Phenylalanine derivatives |
US6309370B1 (en) | 1998-02-05 | 2001-10-30 | Biosense, Inc. | Intracardiac drug delivery |
ES2226413T3 (es) | 1998-02-26 | 2005-03-16 | Celltech Therapeutics Limited | Derivados de fenilalanina como inhibidores de alfa-4 integrinas. |
GB9805655D0 (en) | 1998-03-16 | 1998-05-13 | Celltech Therapeutics Ltd | Chemical compounds |
US6521626B1 (en) | 1998-03-24 | 2003-02-18 | Celltech R&D Limited | Thiocarboxamide derivatives |
GB9811159D0 (en) | 1998-05-22 | 1998-07-22 | Celltech Therapeutics Ltd | Chemical compounds |
GB9811969D0 (en) | 1998-06-03 | 1998-07-29 | Celltech Therapeutics Ltd | Chemical compounds |
HUP0103082A3 (en) * | 1998-06-05 | 2002-12-28 | Astrazeneca Ab | Oxazolidinone derivatives, process for their preparation and pharmaceutical compositions containing them |
GB9812019D0 (en) * | 1998-06-05 | 1998-07-29 | Zeneca Ltd | Chemical compounds |
GB9812088D0 (en) | 1998-06-05 | 1998-08-05 | Celltech Therapeutics Ltd | Chemical compounds |
GB9814414D0 (en) | 1998-07-03 | 1998-09-02 | Celltech Therapeutics Ltd | Chemical compounds |
DE19842415A1 (de) | 1998-09-16 | 2000-03-23 | Merck Patent Gmbh | Pharmazeutische Zubereitung |
GB9821061D0 (en) | 1998-09-28 | 1998-11-18 | Celltech Therapeutics Ltd | Chemical compounds |
GB9821222D0 (en) | 1998-09-30 | 1998-11-25 | Celltech Therapeutics Ltd | Chemical compounds |
GB9825652D0 (en) | 1998-11-23 | 1999-01-13 | Celltech Therapeutics Ltd | Chemical compounds |
GB9826174D0 (en) | 1998-11-30 | 1999-01-20 | Celltech Therapeutics Ltd | Chemical compounds |
EP1140182A2 (en) | 1998-12-23 | 2001-10-10 | G.D. Searle & Co. | Use of a matrix metalloproteinase inhibitor together with an antineoplastic agent, optionally also together with radiation, in the treatment of neoplasia |
CZ20013678A3 (cs) | 1999-04-13 | 2002-07-17 | Basf Aktiengesellschaft | Ligandy integrinového receptoru |
US6518283B1 (en) | 1999-05-28 | 2003-02-11 | Celltech R&D Limited | Squaric acid derivatives |
US6534513B1 (en) | 1999-09-29 | 2003-03-18 | Celltech R&D Limited | Phenylalkanoic acid derivatives |
GB9928568D0 (en) | 1999-12-03 | 2000-02-02 | Zeneca Ltd | Chemical compounds |
US6455539B2 (en) | 1999-12-23 | 2002-09-24 | Celltech R&D Limited | Squaric acid derivates |
WO2001079173A2 (en) | 2000-04-17 | 2001-10-25 | Celltech R & D Limited | Enamine derivatives as cell adhesion molecules |
AU2001253113B2 (en) * | 2000-04-20 | 2005-02-03 | Pharmacia & Upjohn Company | Use of thioamide oxazolidinones for the treatment of bone resorption and osteoporosis |
GB0009803D0 (en) | 2000-04-25 | 2000-06-07 | Astrazeneca Ab | Chemical compounds |
US6545013B2 (en) | 2000-05-30 | 2003-04-08 | Celltech R&D Limited | 2,7-naphthyridine derivatives |
US6403608B1 (en) | 2000-05-30 | 2002-06-11 | Celltech R&D, Ltd. | 3-Substituted isoquinolin-1-yl derivatives |
WO2002004426A1 (en) | 2000-07-07 | 2002-01-17 | Celltech R & D Limited | Squaric acid derivatives containing a bicyclic heteroaromatic ring as integrin antagonists |
EP1305291A1 (en) | 2000-08-02 | 2003-05-02 | Celltech R&D Limited | 3-substituted isoquinolin-1-yl derivatives |
US20030008012A1 (en) * | 2001-02-05 | 2003-01-09 | Pena Lorraine E. | Composition for rectal delivery of an oxazolidinone antibacterial drug |
DE10108995A1 (de) * | 2001-02-23 | 2002-09-05 | Abbott Gmbh & Co Kg | Substituierte Pyrimidinon-Derivate als Liganden von Integrinrezeptoren |
DE10159453A1 (de) * | 2001-12-04 | 2003-06-18 | Merck Patent Gmbh | Verwendung von 1-Phenyl-oxazolidin-2-on-Verbindungen als Protease |
EP1682537B1 (en) * | 2003-11-05 | 2012-03-28 | SARcode Bioscience Inc. | Modulators of cellular adhesion |
ES2439390T3 (es) | 2004-06-04 | 2014-01-22 | The Scripps Research Institute | Composiciones y procedimiento para el tratamiento de enfermedades neovasculares |
PL2444079T3 (pl) | 2005-05-17 | 2017-07-31 | Sarcode Bioscience Inc. | Kompozycje i sposoby leczenia chorób oczu |
CN101360736A (zh) * | 2005-11-23 | 2009-02-04 | 阿斯利康(瑞典)有限公司 | L-丙氨酸衍生物 |
US20080045521A1 (en) * | 2006-06-09 | 2008-02-21 | Astrazeneca Ab | Phenylalanine derivatives |
WO2008093065A1 (en) * | 2007-01-29 | 2008-08-07 | Astrazeneca Ab | L-ALANINE DERIVATIVES AS α5βL ANTAGONISTS |
WO2008125811A1 (en) * | 2007-04-11 | 2008-10-23 | Astrazeneca Ab | N-[HETEROARYLCARBONYL]-S-THIENYL-L-ALANINE DERIVATIVES AS α5β1 ANTAGONISTS |
US20090155176A1 (en) * | 2007-10-19 | 2009-06-18 | Sarcode Corporation | Compositions and methods for treatment of diabetic retinopathy |
US20090258069A1 (en) * | 2008-04-15 | 2009-10-15 | John Burnier | Delivery of LFA-1 antagonists to the gastrointestinal system |
US20090258070A1 (en) * | 2008-04-15 | 2009-10-15 | John Burnier | Topical LFA-1 antagonists for use in localized treatment of immune related disorders |
WO2009139817A2 (en) | 2008-04-15 | 2009-11-19 | Sarcode Corporation | Crystalline pharmaceutical and methods of preparation and use thereof |
WO2009128933A1 (en) * | 2008-04-15 | 2009-10-22 | Sarcode Corporation | Aerosolized lfa-1 antagonists for use in localized treatment of immune related disorders |
WO2011050175A1 (en) | 2009-10-21 | 2011-04-28 | Sarcode Corporation | Crystalline pharmaceutical and methods of preparation and use thereof |
EP3715345B1 (en) | 2012-07-25 | 2024-04-10 | Novartis AG | Preparation of lfa-1 inhibitor |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB834968A (en) * | 1957-08-28 | 1960-05-18 | Robins Co Inc A H | 5-o-alkoxyphenoxymethyl-2-oxazolidones |
DE3205457A1 (de) * | 1982-02-16 | 1983-08-25 | Merck Patent Gmbh, 6100 Darmstadt | Oxazolidin-2-one |
US5053393A (en) * | 1988-07-20 | 1991-10-01 | Monsanto Company | Novel platelet-aggregation inhibitor |
US4948801A (en) * | 1988-07-29 | 1990-08-14 | E. I. Du Pont De Nemours And Company | Aminomethyloxooxazolidinyl arylbenzene derivatives useful as antibacterial agents |
US5084466A (en) | 1989-01-31 | 1992-01-28 | Hoffmann-La Roche Inc. | Novel carboxamide pyridine compounds which have useful pharmaceutical utility |
DE4017211A1 (de) * | 1990-05-29 | 1991-12-05 | Merck Patent Gmbh | Oxazolidinone |
FR2675504B1 (fr) * | 1991-04-16 | 1995-01-27 | Delalande Sa | Derives d'aryl-3 oxazolidinone, leur procede de preparation et leur application en therapeutique. |
DE69329106T2 (de) * | 1992-04-30 | 2001-03-22 | Taiho Pharmaceutical Co Ltd | Oxazolidinderivat und sein pharmazeutisch verträgliches salz |
DE4324393A1 (de) * | 1993-07-21 | 1995-01-26 | Merck Patent Gmbh | 4-Aryloxy- und 4-Arylthiopiperidinderivate |
DE4332384A1 (de) * | 1993-09-23 | 1995-03-30 | Merck Patent Gmbh | Adhäsionsrezeptor-Antagonisten III |
EP0710657B1 (de) * | 1994-11-02 | 1998-08-26 | MERCK PATENT GmbH | Adhäsionsrezeptor-Antagonisten |
DE4439846A1 (de) * | 1994-11-08 | 1996-05-09 | Merck Patent Gmbh | Adhäsionsrezeptor-Antagonisten |
-
1995
- 1995-10-19 EP EP95116483A patent/EP0710657B1/de not_active Expired - Lifetime
- 1995-10-19 ES ES95116483T patent/ES2123889T3/es not_active Expired - Lifetime
- 1995-10-19 DK DK95116483T patent/DK0710657T3/da active
- 1995-10-19 AT AT95116483T patent/ATE170179T1/de not_active IP Right Cessation
- 1995-10-27 AU AU34523/95A patent/AU698987B2/en not_active Ceased
- 1995-10-31 CA CA002161857A patent/CA2161857C/en not_active Expired - Fee Related
- 1995-10-31 PL PL95311194A patent/PL182291B1/pl not_active IP Right Cessation
- 1995-10-31 SK SK1358-95A patent/SK282123B6/sk unknown
- 1995-11-01 RU RU95118721/04A patent/RU2165928C2/ru not_active IP Right Cessation
- 1995-11-01 FI FI955223A patent/FI955223A/fi not_active IP Right Cessation
- 1995-11-01 CZ CZ19952858A patent/CZ290658B6/cs not_active IP Right Cessation
- 1995-11-01 NO NO954366A patent/NO305246B1/no not_active IP Right Cessation
- 1995-11-01 BR BR9505039A patent/BR9505039A/pt not_active IP Right Cessation
- 1995-11-01 CN CN95118144A patent/CN1067384C/zh not_active Expired - Fee Related
- 1995-11-02 TR TR95/01359A patent/TR199501359A2/xx unknown
- 1995-11-02 US US08/552,206 patent/US6602876B1/en not_active Expired - Fee Related
- 1995-11-02 JP JP30858695A patent/JP3810837B2/ja not_active Expired - Fee Related
- 1995-11-02 HU HU9503131A patent/HU217437B/hu not_active IP Right Cessation
- 1995-11-03 MX MX9504630A patent/MX9504630A/es not_active IP Right Cessation
-
1998
- 1998-09-30 US US09/163,481 patent/US6204280B1/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CZ290658B6 (cs) | 2002-09-11 |
MX9504630A (es) | 1997-01-31 |
EP0710657A1 (de) | 1996-05-08 |
SK282123B6 (sk) | 2001-11-06 |
FI955223A0 (fi) | 1995-11-01 |
JPH08225550A (ja) | 1996-09-03 |
SK135895A3 (en) | 1996-06-05 |
HUT74093A (en) | 1996-11-28 |
US6602876B1 (en) | 2003-08-05 |
AU698987B2 (en) | 1998-11-12 |
AU3452395A (en) | 1996-05-09 |
HU9503131D0 (en) | 1995-12-28 |
RU2165928C2 (ru) | 2001-04-27 |
CZ285895A3 (en) | 1996-05-15 |
TR199501359A2 (tr) | 1996-06-21 |
CA2161857A1 (en) | 1996-05-03 |
FI955223A (fi) | 1996-05-03 |
CN1067384C (zh) | 2001-06-20 |
HU217437B (hu) | 2000-01-28 |
NO954366L (no) | 1996-05-03 |
ATE170179T1 (de) | 1998-09-15 |
CN1130626A (zh) | 1996-09-11 |
PL182291B1 (pl) | 2001-12-31 |
PL311194A1 (en) | 1996-05-13 |
NO305246B1 (no) | 1999-04-26 |
NO954366D0 (no) | 1995-11-01 |
BR9505039A (pt) | 1997-10-21 |
EP0710657B1 (de) | 1998-08-26 |
US6204280B1 (en) | 2001-03-20 |
ES2123889T3 (es) | 1999-01-16 |
CA2161857C (en) | 2007-10-09 |
JP3810837B2 (ja) | 2006-08-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE170179T1 (de) | Adhäsionsrezeptor-antagonisten | |
DK0667341T3 (da) | 4-Amino-1-piperidylbenzoylguanidiner som Na+/H+-antiporter-inhibitorer | |
NO952482D0 (no) | Peptider av borsyre, samt fremstilling derav | |
UA41358C2 (uk) | Похідні імідазопіридинів, спосіб їх одержання, фармацевтичний склад та спосіб його одержання | |
GB1238867A (da) | ||
DE3584393D1 (de) | 1-heteroaryl-4-aryl-pyrozolin-5-one. | |
DE59510010D1 (de) | Substituierte 1-phenyl-oxazoliden-2-one Derivate und ihre Verwendung als Adhäsionsrezeptor-Antagonisten | |
FI944513A (fi) | Substituoituja fenyylikarbamaatteja ja fenyyliureoita, niiden valmistus ja niiden käyttö 5-HT-antagonisteina | |
FI955026A (fi) | Alkyyli-5-metyylisulfonyylibentsoyyliguanidiinijohdannaisia | |
FR2729947B1 (da) | ||
NO950574D0 (no) | Akronycinanaloger | |
ES2008631A6 (es) | Un procedimiento para la produccion de derivados de tiofen -3n4-carboxamida. | |
AR241651A1 (es) | Un procedimiento para la preparacion de derivados de nitraminodiarilsulfoxido y procedimiento para la preparacion de composiciones farmaceuticas que los contienen. | |
ES526133A0 (es) | Quinazolinonas sustituidas |